|
AS in the News
This section of our web site will be utilized to feature emerging news about exciting developments around the world that are related to Alport Syndrome.
ALPORT SYNDROME TREATMENTS AND OUTCOME REGISTRY (ASTOR)
The Department of Pediatrics at the University of Minnesota has established an International registry, under the direction of Dr. Clifford E. Kashtan, for the purpose of enabling patient recruitment for clinical natural history studies and therapeutic trials in children and adolescents with Alport Syndrome.
ASTOR is being created in order to facilitate clinical trials for the treatment of Alport Syndrome. This registry will be the first of its kind in North America. Because Alport Syndrome is a rare disorder, recruitment of sufficient participants for meaningful therapeutic trials will require a multi-center effort. The website is www.med.umn.edu/peds/nephr/astor and recruiting of participants has been initiated on ClincalTrials.gov.
BONE-MARROW STEM CELLS MAY REVERSE FEATURES OF ALPORT SYNDROME
A May 2006 study in mice suggests that bone-marrow derived stem cells can repair basement membrane defects and may eventually offer an alternative strategy to dialysis or transplantation in patients with Alport Syndrome. Click here to read the entire article from Medscape.com.
NEPHROGEN, LLC:
Below are some links to articles about a biotechnology company that is investigating using stem cell therapy to restore kidney function.
A TISSUE ENGINEER SOWS CELLS AND GROWS ORGANS:
|
